ETA2023 Poster Presentations Translational 2 (9 abstracts)
Effect of pazopanib in anaplastic thyroid cancer in primary culture
Silvia Martina Ferrari 1 , Giusy Elia 2 , Francesca Ragusa 2 , Sabrina Rosaria Paparo 3 , Valeria Mazzi 2 , Armando Patrizio 4 , Simona Piaggi 3 , Enke Baldini 5 , Marco Centanni 6 , Concettina La Motta 7 , Alessandro Antonelli 2 & Poupak Fallahi 3
1University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy; 2University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area, Pisa, Italy; 3University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy; 4Azienda Ospedaliero-Universitaria Pisana, Department of Emergency Medicine, Pisa, Italy; 5Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy; 6Sapienza, University of Rome, Medico-Surgical Sciences and Biotechnologies, Latina, Italy; 7Department of Pharmacy, University of Pisa, Pisa, Italy
Anaplastic thyroid cancer (ATC) is usually treated with surgery, external hyperfractionated radiation therapy, and chemotherapy. However, because of the aggressiveness of this type of cancer, these treatments allow about 6-10 months of median survival. Therefore, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c-Kit, and its effect in primary human ATC cells (pATC) has not been reported in the literature. We aim to evaluate the antineoplastic effect of pazopanib in pATC in vitro. We collected surgical thyroidal tissues from five patients with ATC, from thyroid biopsy at the moment of first surgical operation, and we tested the effect of pazopanib. We showed an inhibition of proliferation, migration, and invasion, and an increase in apoptosis upon treating pATC cells with pazopanib (P < 0.05). Moreover, the VEGF expression in pATC cells decreased in a significantly manner (P < 0.05) with pazopanib. To sum up we demonstrate the antineoplastic activity of the antiangiogenic inhibitor, pazopanib, in human pATC in vitro.Keywords: anaplastic thyroid cancer; tyrosine kinase inhibitor; primary culture
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more